association of mdm2 snp309 variation with lung cancer risk evidence from 7196 cases and 8456 controls协会mdm2 snp309变异与肺癌风险的证据从7196例病例和7196例对照.pdf

Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls 1 2 1 3 1 Wenlei Zhuo *, Liang Zhang , Bo Zhu , Junjun Ling , Zhengtang Chen * 1 Institute of Cancer, Xinqiao Hospital,Third Military Medical University, Chongqing, China, 2 Department of Environmental Hygiene, College of Preventive Medicine, Third Military Medical University, Chongqing, China, 3 Department of Otolaryngology, Southwest Hospital, Third Military Medical University, Chongqing, China Abstract Background: Evidence suggests that MDM2 T309G polymorphism may be a risk factor for several cancers. Increasing investigations have been conducted on the association of MDM2 T309G polymorphisms with lung cancer risk and have yielded conflicting results. Previous meta-analyses on this issue have reported inconclusive data. The aim of the present study was to derive a more precise estimation of the relationship. Methods and Findings: Updated meta-analyses examining the association between MDM2 T309G polymorphism and lung cancer risk were performed. Separate analyses on ethnicity, smoking status, histological types and gender as well as source of controls were also implemented. Eligible studies were identified for the period up to Feb 2012. Lastly, ten publications including eleven case-control studies were selected for analysis. The overall data failed to indicate a significant association between MDM2 T309G polymorphism and lung cancer risk (GG vs TT OR = 1.14; 95%CI = 0.9521.37; dominant model: OR = 1.05; 95%CI = 0.92 21.19; recessive model: OR = 1.12; 95%CI = 0.9921.27). In a subgroup analysis by smoking status, increased lung cancer risk was shown among never-smokers (GG vs TT: OR = 1.76; 95%CI = 1.3622.29; dominant model